Tangible Shareholders Equity: The value shareholders equity less intangible assets.
NewAmsterdam Pharma Company N.V. (NAMS) had Tangible Shareholders Equity of $778.03M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$19.14M |
|
$-17.36M |
|
-- |
|
$19.14M |
|
$54.78M |
|
$-35.63M |
|
$18.27M |
|
$-17.36M |
|
$-17.36M |
|
$-17.36M |
|
$-17.36M |
|
$-17.36M |
|
$-17.36M |
|
$-35.63M |
|
$-35.59M |
|
118.56M |
|
118.56M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$769.85M |
|
$0.31M |
|
$45.26M |
|
$815.11M |
|
$36.51M |
|
-- |
|
$0.10M |
|
$36.62M |
|
$778.50M |
|
|
Tangible Shareholders Equity |
$778.03M |
$778.50M |
|
112.51M |
|
| Cash Flow Statement Financials | |
$-74.14M |
|
$-156.28M |
|
$9.94M |
|
$771.74M |
|
$563.86M |
|
$-207.88M |
|
$30.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.08 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-186.13% |
|
-186.13% |
|
-- |
|
-90.70% |
|
-90.70% |
|
$-74.24M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-2.23% |
|
-2.23% |
|
-2.13% |
|
-2.23% |
|
$6.92 |
|
$-0.63 |
|
$-0.63 |
|